Moreover, the 36-month beta value for CRBP is 3.19. Analysts have varying opinions on the stock, with 7 analysts rating it as a “buy”, 3 as “overweight”, 0 as “hold”, and 0 as “sell”.
The public float for CRBP is 10.70M and currently, short sellers hold a 17.47% of that float. On July 04, 2025, CRBP’s average trading volume was 173.75K shares.
CRBP stock’s latest price update
The stock price of Corbus Pharmaceuticals Holdings Inc (NASDAQ: CRBP) has plunged by -0.52% when compared to previous closing price of $7.75, but the company has seen a -3.87% decline in its stock price over the last five trading sessions. globenewswire.com reported 2025-06-25 that NORWOOD, Mass., June 25, 2025 (GLOBE NEWSWIRE) — Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus” or the “Company”), a clinical-stage company focused on oncology and obesity, today announced the dosing of the first participant in the PD-1 combination arm of its Phase 1 study investigating CRB-701 in solid tumors (the Phase 1 Western study). Participants in this arm of the study are being randomized to the 2.7 mg/kg and 3.6 mg/kg cohorts in combination with Keytruda® (pembrolizumab).
CRBP’s Market Performance
Corbus Pharmaceuticals Holdings Inc (CRBP) has seen a -3.87% fall in stock performance for the week, with a -7.11% decline in the past month and a 48.27% surge in the past quarter. The volatility ratio for the week is 7.34%, and the volatility levels for the past 30 days are at 6.71% for CRBP. The simple moving average for the last 20 days is -7.38% for CRBP stock, with a simple moving average of -36.36% for the last 200 days.
Analysts’ Opinion of CRBP
H.C. Wainwright gave a rating of “Buy” to CRBP, setting the target price at $80 in the report published on July 22nd of the previous year.
CRBP Trading at -0.67% from the 50-Day Moving Average
After a stumble in the market that brought CRBP to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -87.54% of loss for the given period.
Volatility was left at 6.71%, however, over the last 30 days, the volatility rate increased by 7.34%, as shares sank -8.97% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +15.25% upper at present.
During the last 5 trading sessions, CRBP fell by -3.87%, which changed the moving average for the period of 200-days by -86.19% in comparison to the 20-day moving average, which settled at $8.32. In addition, Corbus Pharmaceuticals Holdings Inc saw -84.39% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at CRBP starting from Jenkins John Kenneth, who sold 2,783 shares at the price of $7.35 back on May 30 ’25. After this action, Jenkins John Kenneth now owns 33 shares of Corbus Pharmaceuticals Holdings Inc, valued at $20,465 using the latest closing price.
Altmeyer Anne, the Director of Corbus Pharmaceuticals Holdings Inc, sale 1,392 shares at $7.25 during a trade that took place back on May 30 ’25, which means that Altmeyer Anne is holding 1,391 shares at $10,096 based on the most recent closing price.
Stock Fundamentals for CRBP
The total capital return value is set at -0.46%. Equity return is now at value -44.89%, with -37.86% for asset returns.
Based on Corbus Pharmaceuticals Holdings Inc (CRBP), the company’s capital structure generated 0.02 points at debt to capital in total, while cash flow to debt ratio is standing at -17.6. The debt to equity ratio resting at 0.02. The interest coverage ratio of the stock is -56.99.
Currently, EBITDA for the company is -37.74 million with net debt to EBITDA at 0.33. The liquidity ratio also appears to be rather interesting for investors as it stands at 11.82.
Conclusion
To wrap up, the performance of Corbus Pharmaceuticals Holdings Inc (CRBP) has been bad in recent times. The stock has received a bullish of “buy” and “hold” ratings from analysts. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
